Actively Recruiting
Phase IIIa Study of Single Subretinal Injection of RRG001 Gene Therapy for Neovascular Age-related Macular Degeneration in Adults Aged 50 and Older
Led by Shanghai Refreshgene Technology Co., Ltd. · Updated on 2024-11-14
48
Participants Needed
1
Research Sites
245 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of RRG001, a gene therapy, through a Phase IIIa study in people with neovascular age-related macular degeneration nAMD. This study involves a single subretinal injection and aims to better understand how well the treatment works and how safe it is for this condition, which affects the eyes and can lead to vision loss. The study is designed with two stages a dose-escalation phase and a dose-expansion phase. During the dose-escalation phase, participants will receive one of four preset doses of RRG001 via a single subretinal injection, with 3 to 6 subjects per dose group. Following safety assessments, the dose-expansion phase will enroll additional subjects at the selected doses to further evaluate treatment effects. Overall, around 24 subjects will participate across both phases. Participants will be closely monitored for safety and how well the treatment is tolerated over a 52-week period. Researchers will assess vision and other eye health measures at regular intervals. Safety checks and evaluations will guide any adjustments to dosing or sample size. The entire study may last several months to a year, with continuous follow-up to observe outcomes after the injection.
CONDITIONS
Brief Title
Safety and Efficacy of RRG001 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
Research Team
X
Xiaorong Li, Master
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here